F9170 peptide

F9170 peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-GWEALKYLWNLLQYW-OH

H-Gly-Trp-Glu-Ala-Leu-Lys-Tyr-Leu-Trp-Asn-Leu-Leu-Gln-Tyr-Trp-OH

15

95.08%

C₁₀₀H₁₃₅N₂₁O₂₂

1983.26

Synthetic

Powder

F9170 is a peptide identified from the cytoplasmic region of the HIV-1 envelope glycoprotein (Env, gp120-gp41) which is able to inactivate HIV-1 virions and induce necrosis of HIV-1 infected cells. F9170 can enter the brain and lymph nodes and specifically targets the conserved cytoplasmic tail of HIV-1 Env to disrupt the integrity of the viral membrane. F9170 short term administration can control viral loads to below the limit of detection in chronically SHIV infected macaques.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Wang et al (2020) An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells. Sci Transl Med. 12(546):eaaz2254 PMID: 32493792

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.